Log in to your Inderes Free account to see all free content on this page.
IRLAB Therapeutics
10.7
SEK
-0.47 %
IRLAB A
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
2 following
-0.47%
-0.47%
-16.73%
-18.32%
-20.74%
+42.67%
-75.68%
-70.25%
-7.72%
IRLAB Therapeutics is a Swedish research and pharmaceutical company. The research is based on the company's own research platform and specializes in the treatment of brain diseases, commonly referred to as neurodegenerative diseases. At the present, the company holds drug candidates specializing in, among other things, Parkinson's disease. The head office is located in Gothenburg.
Read moreMarket cap
554.99M SEK
Turnover
135.13K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Financial calendar
12.2.
2025
Annual report '24
7.5.
2025
Interim report Q1'25
21.5.
2025
General meeting '24
ShowingAll content types
IRLAB to present at Redeye Technology & Life Science Day on December 3, 2024
Nomination committee appointed for IRLAB’s annual general meeting 2025
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio